~~<i id='95BC96554B'><strike id='95BC96554B'><tt id='95BC96554B'><pre id='95BC96554B'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

leisure time

author：Wikipedia 2025-09-29 21:14:16 - browse：494

MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around targeted chemotherapy treatments.

The deal includes a $4 billion upfront payment and an additional $1.5 billion over the next two years. Up to $16.5 billion more is on the table depending on the success of the drugs in development.

The announcement on Thursday night in the United States came on the eve of one the cancer field’s biggest annual conferences, the European Society for Medical Oncology Congress, being held this year in Madrid.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Readout LOUD podcast: A CRISPR milestone, biotech mixology

hotspot

focus

knowledge

focus

hotspot

knowledge

OlderadultsandfirstresponderswaitinlinetoreceiveaCovid-19vaccineattheLakesRegionalLibraryinDecember2

WSS

In key trial, Verve's treatment lowers cholesterol levels in patients

Hospitals look to new technology to keep health care workers safe

Childhood cancer progress stalls for Black, Hispanic kids: Report

Congress must reauthorize a committee to support older Americans

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

A preacher's new calling: Diversifying neuroscience research

focus

leisure time

hotspot

Continuity nursing helped my family in our darkest PICU moments

NYU radiologists take on the challenge of expensive MRI machines

BioMarin wins approval for gene therapy to treat hemophilia A

In shift, Texas to cover initial consult for Afghan baby's gene therapy

United colonoscopy coverage change 'may cost lives,' doctors say

Stories you might have missed in 2023: health, science, medicine

United colonoscopy coverage change 'may cost lives,' doctors say

Gain of function research would be limited under House proposal

Wildfire smoke exposes gaps in outdoor worker protections

FDA's Woodcock to retire early next year

focus

Hospitals look to new technology to keep health care workers safe

Why medical students are struggling with mental health

CRISPR pioneers react to Casgevy, first gene

Boston Scientific acquires urology company Axonics for $3.7 billion

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Anthos stroke drug appears safer than common blood thinner

knowledge

focus

hotspot

knowledge